Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT04023721 Terminated - Hepatitis B Clinical Trials

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Start date: June 18, 2019
Phase: Phase 2
Study type: Interventional

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.

NCT ID: NCT03932513 Terminated - Hepatitis B Clinical Trials

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

NCT ID: NCT03887702 Terminated - Clinical trials for Malignant Solid Neoplasm

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

Start date: January 17, 2020
Phase: Phase 3
Study type: Interventional

This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Anti-HBV therapy acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer therapy for solid tumors.

NCT ID: NCT03820258 Terminated - Clinical trials for Hepatitis C Virus Infection

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) in pediatric participants with chronic hepatitis C virus (HCV) infection.

NCT ID: NCT03797066 Terminated - Clinical trials for Hepatitis C, Chronic

ATTIC - Access To Treat in the Community

ATTIC
Start date: March 23, 2019
Phase: Phase 4
Study type: Interventional

The study is looking at the potential of utilizing a "point of care" test and treat pathway; using the DDA called Zepatier for achieving SVR in an homeless population who have tested positive for genotype 1 or 4 HCV.

NCT ID: NCT03780543 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Start date: December 20, 2018
Phase: Phase 2
Study type: Interventional

Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.

NCT ID: NCT03762681 Terminated - Clinical trials for Hepatitis B Virus Infection

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Start date: December 14, 2018
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).

NCT ID: NCT03723824 Terminated - Chronic Hepatitis c Clinical Trials

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Start date: February 14, 2019
Phase: Phase 4
Study type: Interventional

Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.

NCT ID: NCT03534141 Terminated - Clinical trials for Hepatocellular Carcinoma

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

MHALT
Start date: July 7, 2018
Phase: N/A
Study type: Interventional

Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies). Patients who experience AKI after liver transplantation have higher mortality, increased graft loss, longer hospital and intensive care unit stays, and more progression to chronic kidney disease compared with those who do not. In this study, half of the participants will have their body temperature cooled to slightly lower than normal (mild hypothermia) for a portion of the liver transplant operation, while the other half will have their body temperature maintained at normal. The study will evaluate if mild hypothermia protects from AKI during liver transplantation.

NCT ID: NCT03500562 Terminated - Chronic Hepatitis C Clinical Trials

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Start date: May 8, 2018
Phase:
Study type: Observational

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy